David Zacut, MD
Chairman of the Board
Dr. Zacut has served as Brainsway's Chairman of the Board of Directors since the company's inception, and has been providing consulting services to Brain Research Services since May 2001. Since 1983, Dr. Zacut has been working as a senior practicing physician at Hadassah Hospital, and from 1994 through 2003, he served as a managing director of several large medical centers. In addition, Dr. Zacut serves as a director of several private companies, including Brain Research Services. Dr. Zacut holds an M.D. degree from the Hebrew University of Jerusalem.
Chief Executive Officer
Mr. Michlin brings two decades of experience in growing biomedical organizations. His proficiency in corporate finance, capital markets and business management and development has played a crucial role in the success of leading organizations throughout the Israeli biotech industry. He joined Brainsway in 2015 serving as a director on its board providing exceptional guidance.
He brings extensive expertise in steering biomedical companies to success. Yaacov possesses the right blend of strategic acumen, interpersonal skills, relationship assets and management capabilities.
For the past eight years, Mr. Michlin has served as president and CEO of Yissum, the technology transfer company of Israel's Hebrew University in Jerusalem. At Yissum, he facilitated and oversaw numerous corporate transactions and initiatives in partnership with corporations across the globe and funded and served as chairman of few companies including Integra Holdings, a healthcare investment company and Agrinnovation an investment fund focusing on Agriculture and food sciences. Mr. Michlin also served as chairman for QLIGHT Nanotech Ltd., a developer of semiconductors and nanocrystals, which he led from the company's founding until its acquisition by Merck. He also served as co-chairman of ITTN, the Israeli organization for technology transfer.
Prior to Yissum, Mr. Michlin practiced as a corporate lawyer, advising on major corporate matters including mergers and acquisitions, capital raising and initial public offerings for clients including mainly Teva Pharmaceutical Industries. Mr. Michlin is a lawyer and economist by training, and holds an MBA from the Technion in high-tech company management.
Ms. Mitrany received her B.A. in economics in 1994 and M.B.A. in finance in 1997, both from Tel-Aviv University.
With over 20 years of experience in finance, M&A and business operations, primarily in the pharmaceutical industries, Ms. Mitrany provides broad and experienced knowledge of the global pharmaceutical business and industry.
Ms. Tsafrir is an expert in economics, accounting and banking. She is an independent consultant providing financial consulting to organizations and individuals, as well as a director in several enterprises, including Altusher Shacham Investments, Kadimastam and the Mediterranean Towers. She worked at Discount Bank for 3 years as a Business Development Manager, and at Bank Leumi for 15 years in a variety of roles, establishing and managing the branch of capital market customers, and serving as a commercial banking manager and a macro financial expert. Ms. Tsafrir earned a BA, Cum Laude, in Finance, and an MA in Finance, both from Tel Aviv University.
Dr. Yuval Lavi, M.D has been Senior Physician at Hadassah Hospital in Jerusalem, Israel since 1990. Dr. Lavi has been Director of Brainsway Ltd. since December 2006. He received his medical degree from Ben-Gurion University in Beer Sheva, Israel.
Abraham Zangen, PhD
Professor Abraham Zangen is the head of the brain stimulation and behavior lab in the department of Life Sciences at the Ben-Gurion University in Israel. His research is directed to identification and understanding of altered neuroplasticity in psychiatric disorders - primarily depression, addiction and ADHD. He studies the effects of repeated brain stimulation on markers for neuroplasticity and on behavioral outcomes in psychiatric patients as well as in animal models for depression and addiction. He has developed unique deep transcranial magnetic stimulation coils for the treatments of depression, addiction and ADHD. The device he has developed for the treatment of depression was already approved by the FDA and other regulatory bodies, while other versions of his device are being tested for their efficacy in other psychiatric and neurological disorders. His early work in this field led to establishment of Brainsway, a company that commercializes the coils he developed with his colleagues.
Prof. Zangen has published over 100 peer reviewed articles, reviews and book chapters. He has been was rewarded with numerous personal prizes for his scientific achievements including the Medical Futures Innovation Award in London, The Juludan Prize at the Technion, and received several distinguished research grants including NIH, H2020 and ISF funding.
Yiftach Roth, PhD
As one of Brainsway's founders, Yiftach Roth has served as the company's Research and Development Manager since May 2006, and as a member of our Board of Directors since November 2006. From 2003 through 2006, Dr. Roth worked in the Advanced Technology Center of the Chaim Sheba Medical Center at Tel Hashomer as a researcher in the field of Magnetic Resonance Imaging (MRI). His primary research interests are TMS and Magnetic Resonance Imaging (MRI), and he was one of the two key inventors of our patented Deep TMS coil. Dr. Roth holds B.Sc. and M.Sc. degrees in Physics and a Ph.D. in Medical Physics from Tel Aviv University.
Mr. Hagai is a businessman who serves as director of several private and public companies. He served as Chairman of the Board of public companies and has extensive business experience and expertise in various fields.
Mr. Gavriel Magen has been the Chief Executive Officer of Polybid Ltd., a leader in the field of expanded polystyrene products and the largest Expandable Polystyrene (EPS) producer in Israel since January 1, 2009. From May 1, 2007 to January 31, 2008, he served as the Chief Executive Officer of Plassim Ltd., an Israeli company that manufactures pipes for numerous applications, including water supply, sewerage and drainage, irrigation, gas, telecom, and industrial uses. Prior to such time, commencing on January 1, 2000, Mr. Amgen served as the Chief Executive Officer of Oran Pal mach Subba Agricultural Cooperative Society Ltd., an Israeli producer of safety glass and strengthened or reinforced glass. He has been a Director of Brains way Ltd. since December 2006. Mr. Magen holds a B.A. in business administration from the Ruppin Academic Center in Hefer Valley, Israel.
* Brainsway and the Brainsway logo are trademarks of Brainsway Ltd.